-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Erlotinib is a cancer medication that is primarily used to treat non-small cell lung cancer and pancreatic cancer.
It works by inhibiting the activity of a protein called tyrosine kinase, which is involved in the growth and division of cancer cells.
Erlotinib is known by the brand name Tarceva, and it has been widely used for over a decade in the treatment of these types of cancer.
One of the main benefits of erlotinib is its relatively mild side effect profile.
While it can cause some nausea and diarrhea, these are generally the most common side effects and tend to be manageable with supportive care.
Additionally, erlotinib has been shown to have a good safety profile in both clinical trials and real-world use.
However, like all medications, erlotinib can cause some serious side effects.
These include rash, which can be severe in some cases; liver problems; and interstitial lung disease, which is a type of lung inflammation.
It's important for patients to report any side effects to their doctor immediately so that they can be properly managed.
In addition to its potential side effects, it's also important to note that erlotinib can interact with other medications.
This is especially important for patients who are taking medications for heart arrhythmias or who are taking warfarin, a blood thinner.
Patients should always talk to their doctor about all medications they are taking before starting treatment with erlotinib.
Despite the potential side effects, erlotinib has been shown to be an effective treatment option for patients with non-small cell lung cancer and pancreatic cancer.
In clinical trials, erlotinib has been shown to improve survival and delay the progression of cancer in these patients.
Additionally, it has been shown to be effective in treating patients with advanced cancer who have already received other treatments.
Overall, the safety profile of erlotinib is generally good, and it has been shown to be an effective treatment option for patients with non-small cell lung cancer and pancreatic cancer.
However, like all medications, it's important to be aware of the potential side effects and to talk to your doctor about any concerns you may have.
Additionally, it's important to be aware of the potential drug interactions and to always disclose all medications you are taking to your healthcare provider.